参考文献
[1] SUBHAMOY C, CHARLES C, DENIZ D, et al. Preclinical analysis identifies predictive biomarker and potential pathways of resistance to lurbinectedin treatment in small cell lung cancer[EB/OL].(2023-04-14)[2023-04-20]. https://www.abstractsonline.com/pp8/#!/10828/presentation/9673.
[2] APARNA G, KEDAR S V, ROBERT H. High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models[EB/OL]. (2023-04-14)[2023-04-20]. https://www.abstractsonline.com/pp8/#!/10828/presentation/4120.
[3] MARTA M D, GEMA S N, MARIA J G. Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SLFN11 are biomarkers for a better response[EB/OL].(2023-04-14)[2023-04-20]. https://www.abstractsonline.com/pp8/#!/10828/presentation/6768.